Presence and Onset of Chronic Kidney Disease as a Factor Involved in the Poor Prognosis of Patients with Essential Thrombocythemia
Table 1
Patient characteristics.
Characteristics at ET diagnosis
All patients n = 73
With CKD at ET diagnosis n = 21 (28.8%)
Without CKD at the time of ET diagnosis n = 52 (71.2%)
value
Age, median; years (range)
69 (29–89)
77 (45–89)
68 (29–89)
0.001
Female, n (%)
38 (52)
9 (43)
29 (56)
0.438
Male, n (%)
35 (48)
12 (57)
23 (44)
WBC, median; ×109/L (range)
9.6 (4.0–48.6)
10.3 (7.3–35.8)
9.1 (4.0–48.6)
0.070
Neu, median; % (range)
70.8 (50.1–90.3)
71.7 (53.0–90.3)
70.8 (50.1–88.9)
0.446
RBC, median; ×1012/L (range)
4.82 (2.54–6.72)
5.29 (2.54–6.72)
4.71 (3.05–6.72)
0.027
Hb, median; g/dL (range)
14.0 (7.5–16.4)
14.1 (7.5–16.4)
13.9 (7.8–16.1)
0.869
Hct, median; % (range)
43.0 (23.6–54.6)
43.9 (23.6–54.6)
42.6 (25.6–49.2)
0.249
Plt, median; ×109/L (range)
879 (450–2648)
889 (452–2648)
868 (450–1833)
0.942
CRP median; mg/dL (range)
0.07 (0.01–4.52)
0.13 (0.02–3.63)
0.07 (0.01–4.52)
0.093
LD, median; U/L (range)
239 (123–609)
273 (179–561)
214 (123–609)
0.002
BUN, median; mg/dL (range)
14.4 (6.9–37.6)
19.0 (9.5–37.6)
13.7 (6.9–26.2)
0.002
Cr, median; mg/dL (range)
0.7 (0.4–2.1)
1.0 (0.7–2.1)
0.6 (0.4–0.9)
<0.001
eGFR, median; ml/min/1.73 m2 (range)
80.2 (25.2–133.9)
52.3 (25.2–59.5)
87.1 (62.6–133.9)
<0.001
Uric acid, median; mg/dL (range)
5.1 (2.3–8.7)
6.6 (3.7–8.5)
4.8 (2.3–8.7)
<0.001
JAK2V617F mutation, n (%)
49a (67.1)
19 (90.5)
30a (57.7)
0.007
CALR mutation, n (%)
12 (16.4)
2 (9.5)
10 (19.2)
0.489
MPL mutation, n (%)
4a (5.5)
0 (0)
4a (7.7)
0.318
Chromosome abnormality, n (%)
4 (5.5)
2 (9.5)
2 (3.8)
0.403
History of thrombosis, n (%)
22 (30.1)
10 (47.6)
12 (23.1)
0.051
History of hemorrhagic events, n (%)
4 (5.5)
1 (4.8)
3 (5.8)
1.000
Cardiovascular risk factors, n (%)
48 (65.8)
18 (85.7)
30 (57.7)
0.029
Heart failure, n (%)
13 (17.8)
8 (61.9)
5 (9.6)
0.007
Splenomegaly, n (%)
13 (17.8)
4 (19.0)
9 (17.3)
1.000
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ET, essential thrombocythemia. values of <0.05 are highlighted in bold. Percentages in parentheses refer to percentages in each group. aOne patient harbored JAK2V617F and MPLW515L mutations.
